- Home
- C vs BMY Comparison
C vs BMY Comparison
Compare C & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- C
- BMY
- Stock Information
- Founded
- C 1812
- BMY 1887
- Country
- C United States
- BMY United States
- Employees
- C N/A
- BMY N/A
- Industry
- C Major Banks
- BMY Biotechnology: Pharmaceutical Preparations
- Sector
- C Finance
- BMY Health Care
- Exchange
- C Nasdaq
- BMY Nasdaq
- Market Cap
- C 127.5B
- BMY 120.5B
- IPO Year
- C N/A
- BMY N/A
- Fundamental
- Price
- C $73.99
- BMY $59.19
- Analyst Decision
- C Buy
- BMY Hold
- Analyst Count
- C 14
- BMY 14
- Target Price
- C $86.71
- BMY $58.00
- AVG Volume (30 Days)
- C 16.9M
- BMY 12.9M
- Earning Date
- C 04-15-2025
- BMY 04-24-2025
- Dividend Yield
- C 3.01%
- BMY 4.19%
- EPS Growth
- C 47.03
- BMY N/A
- EPS
- C 5.94
- BMY N/A
- Revenue
- C $71,363,000,000.00
- BMY $48,300,000,000.00
- Revenue This Year
- C $20.06
- BMY N/A
- Revenue Next Year
- C $3.69
- BMY N/A
- P/E Ratio
- C $12.53
- BMY N/A
- Revenue Growth
- C 0.94
- BMY 7.32
- 52 Week Low
- C $53.51
- BMY $39.35
- 52 Week High
- C $84.74
- BMY $63.33
- Technical
- Relative Strength Index (RSI)
- C 53.05
- BMY 48.76
- Support Level
- C $66.73
- BMY $59.46
- Resistance Level
- C $72.98
- BMY $61.34
- Average True Range (ATR)
- C 1.95
- BMY 1.61
- MACD
- C 0.67
- BMY -0.11
- Stochastic Oscillator
- C 95.54
- BMY 16.70
About C Citigroup Inc.
Citigroup is a global financial-services company doing business in more than 100 countries and jurisdictions. Citigroup's operations are organized into five primary segments: services, markets, banking, US personal banking, and wealth management. The bank's primary services include cross-border banking needs for multinational corporates, investment banking and trading, and credit card services in the United States.
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.